Miami, FL — November 4, 2025 — Leads & Copy — Summit Therapeutics Inc. (NASDAQ: SMMT) will participate in and present at four upcoming investor conferences. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the UBS Global Healthcare Conference, Jefferies Global Healthcare Conference, Citi’s 2025 Global Healthcare Conference, and Evercore Healthcare Conference.
The fireside chats will be available live on Summit’s website, with archived versions available following the presentations.
Ivonescimab, also known as SMT112 in Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining immunotherapy via blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule, and is currently engaged in multiple Phase III clinical trials by Akeso Inc. (HKEX Code: 9926.HK).
Summit began its clinical development of ivonescimab in NSCLC, and intends to open clinical trial sites in the United States for the Phase III study in CRC by the end of 2025.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Summit Therapeutics Inc. was founded in 2003, is headquartered in Miami, Florida. Robert W. Duggan and Dr. Maky Zanganeh remain as Co-CEOs.
Source: Summit Therapeutics Inc.
